Most cancer patients have mutations in the p53 gene, and the remaining possess defective wild-type p53 pathways.244 Accordingly, we primarily focus on inhibiting the expression of mutant p53 protein and restoring the function of wild-type p53 to retard further tumor development through small molecule compounds so as to achieve the goal of effective treatment of cancer. This evidence concerns the gene TP53 and neoplasm.